This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

TRADE NEWS: Agilent Technologies Expands Catalog Of SureFISH Break-Apart Probes

Agilent Technologies Inc. (NYSE: A) today introduced SureFISH ALK, ROS1 and RET break-apart translocation probes, expanding its offering of oligonucleotide-based fluorescent in situ hybridization (FISH) products. Agilent now offers more than 450 FISH probes.

The majority of FISH probes available on the market use BAC technology. BAC probes target repeat regions, and probe choices are limited by BAC availability. As a result, these probes often show nonspecific signals, target sequences outside the region of interest, and have suboptimal signal strength. Because Agilent SureFISH probes use high-fidelity oligos designed in silico, the probes are repeat-free and able to target specific sequences of interest. In addition, Agilent’s oligo-based probes have complete flexibility in both size and number of oligos per region.

For ALK, ROS1 and RET probes, Agilent has fine-tuned the probe size and oligo density to give brighter, more balanced signals than BACs. For ALK and RET break-aparts, Agilent used a unique micro-gap design to minimize distance between child probes, enabling tight signal co-localization.

“Our new ALK, RET and ROS1 break-apart SureFISH probes are designed to provide brighter, more balanced and better co-localized signals than similar probes on the market today,” said Jacob Thaysen, vice president and general manager for Agilent’s Diagnostics and Genomics business. “This enables quicker and more accurate detection of translocation events.”

Customers can find and purchase SureFISH probes on the Agilent Genomics website, which enables them to search for probes based on chromosome location, cytoband or genes of interest. The chromosome browser also includes hybridization images, allowing users to see the probe performance prior to purchase.

For more information about Agilent SureFISH probes, visit www.agilent.com/genomics/SureFISH.

About Agilent in Genomics

Agilent is a global leader in target enrichment for next-generation sequencing and genomic microarrays. The Agilent SureSelect and HaloPlex target enrichment systems enable researchers to easily choose which segments of a genome to sequence, avoiding the time and expense needed to sequence the entire genome. HaloPlex offers a same day sample-to-sequencer workflow; SureSelect can accurately capture whole exomes and whole methylomes in a single reaction. These are just two products arising from Agilent’s expertise in synthesizing custom complex mixtures of long oligonucleotides gained in microarray manufacturing. Additional product lines built on this core technology include microarrays for genome-wide measurement of gene expression and for comparative genomics hybridization, as well as SureFISH, a highly specific and sensitive product line for oligonucleotide fluorescent in situ hybridization. In addition to oligonucleotide-based products, Agilent offers a microfluidic bioanalyzer to measure sample quality, and a full set of reagents, hardware, methods and bioinformatics software for genomic experiments.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs